2023 Annual NEALS Meeting
The 22nd Annual NEALS Meeting will be returning to the Opal Sands Resort in Clearwater Beach, Florida!
The mission of the Northeast Amyotrophic Lateral Sclerosis Consortium® (NEALS) is to rapidly translate scientific advances into clinical research and new treatments for people with Amyotrophic Lateral Sclerosis (ALS) and motor neuron disease.
With support from The ALS Association, NEALS provides up-to-date information for finding both federally and privately funded clinical studies focusing on ALS and motor neuron diseases.
Contact an ALS Specialist
NEALS wants to make it easy for you to connect with a specialist. Use our search feature to find contact information for specialists in over 140 locations across the country and abroad.
Neurodegenerative Alzheimer's Disease and Amyotrophic Lateral Sclerosis (NADALS) Basket Proof of Concept Trial Including Asymptomatic Individuals Using BaricitinibThis is an open-label, biomarker-driven basket trial of baricitinib in people with subjective cognitive disorder, mild cognitive impairment, Alzheimer's disease (AD), Amyotrophic lateral sclerosis…
A Phase 1/2 Two-center, Double-blind, Randomized, Placebo-controlled Multi-period Crossover (N-of-1) Study to Evaluable the Feasibility, Safety, and Efficacy of TJ-68 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Muscle CrampsThe primary objective of the study is to demonstrate the safety and potential efficacy of TJ-68 for improving muscle cramps in participants with ALS based on a two-site, randomized,…
Prospective Randomized Open, Blinded Endpoint (PROBE) Study of AMDX-2011P as a Retinal Tracer in Subjects With Neurodegenerative Diseases Associated With Amyloidogenic ProteinopathyThe purpose of this research study is to assess safety and tolerability of a single intravenous (given through a vein) dose of the investigational retinal tracer AMDX-2011P in patients with…
A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031)The purpose of this study is to assess the long-term safety and tolerability of reldesemtiv in patients with ALS who have successfully completed dosing in the Phase 3 clinical trial, CY 5031 (also…
Optimizing BCI-FIT: Brain Computer Interface - Functional Implementation ToolkitThis project adds to non-invasive BCIs for communication for adults with severe speech and physical impairments due to neurodegenerative diseases. Researchers will optimize & adapt BCI signal…
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Assess the Efficacy, Safety, Tolerability, PK, and Biomarker Effects of PTC857 in Adult Subjects With Amyotrophic Lateral Sclerosis (CARDINALS)This study will assess the effects and safety of PTC857 treatment in participants diagnosed with ALS.
Trials News & Events
Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS
The FDA is continuing its review of tofersen with a Prescription Drug User Fee Act action date of April 25, 2023.
Amylyx Pharmaceuticals Announces FDA Approval of RELYVRIO™ for the Treatment of ALS
RELYVRIO (previously known as AMX0035 in the U.S.) is an oral, fixed-dose combination therapy for the treatment of adults with ALS
"Healey & AMG Center & the Northeast ALS Consortium announce results in platform trial with pridopidine," published by the Sean M. Healey & AMG Center for ALS
"Amylyx Pharmaceuticals Announces Completion of Enrollment in Global Phase 3 PHOENIX Trial of AMX0035 in ALS," published by Amylyx Pharmaceuticals
"BrainStorm Cell Therapeutics Partners with NEALS, The ALS Association, and I AM ALS to Provide Public Access to Biospecimens from NurOwn's Phase 3 ALS Study," published by BrainStorm Cell Therapeutics Inc.